Briefing
MRD GATE RCC: observation instead of adjuvant pembrolizumab when MRD is undetectable
Phase 2 study in which patients with resected clear-cell renal cell carcinoma who would otherwise receive adjuvant pembrolizumab are observed if molecular residual disease is not detected, and continue pembrolizumab if it is.
- Design: Phase 2 · Recruiting